Predictive Factors of Pseudoprogression in Vestibular Schwannoma Treated with Fractionated Stereotactic Radiotherapy

被引:0
|
作者
Lo, A. W. S. [1 ]
Nyaw, S. F. [2 ]
Mui, W. H. [2 ]
Huang, J. J. [2 ]
Kam, K. M. [3 ]
Wong, C. S. [2 ]
机构
[1] Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Clin Oncol, Tuen Mun, Hong Kong, Peoples R China
[3] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Happy Valley, Hong Kong, Peoples R China
来源
HONG KONG JOURNAL OF RADIOLOGY | 2019年 / 22卷 / 03期
关键词
Neuroma; acoustic; Radiotherapy; Risk factors; ACOUSTIC NEUROMAS; RADIOSURGERY; RADIATION; MANAGEMENT; EXPANSION; SURGERY;
D O I
10.12809/hkjr1916934
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Fractionated stereotactic radiotherapy (FSRT) is a well-established treatment for vestibular schwannoma (VS). Tumour pseudoprogression may lead to worsening symptoms leading to the necessity of urgent salvage surgery. This study aimed to assess the predictive factors of pseudoprogression and treatment related toxicities in VS treated with FSRT. Methods: This retrospective cohort study included all patients with VS treated with FSRT between 1999 and 2015. Risk factors assessed included sex, age, previous surgical resection, tumour diameter, gross tumour volume, planning target volume, overall treatment time, equivalent dose in 2-Gy fractions, and the presence of brainstem or cerebellar compression prior to radiotherapy. Fisher's exact test and two-sample t test were used for statistical analysis. Results: Eighteen patients were included. The median follow-up time was 80.3 months. The overall disease control rate after FSRT was 94.4%. Of the 18 patients, one (5.6%) developed local tumour progression, seven (38.9%) underwent tumour pseudoprogression; and 10 (55.6%) had stable disease. Median time to tumour pseudoprogression was 8.63 months (range, 4.5-13.1 months). Tumours with pseudoprogression and those with at least stable disease had a mean diameter of 2.7 cm and 2.1 cm, respectively (p = 0.18). The mean treatment planning target volume in the pseudoprogression group was larger than that in the non-progression group with volume measured (22.2 cc vs. 10.0 cc; p = 0.04). Patients with brainstem or cerebellar compression observed on magnetic resonance imaging before radiotherapy were associated with a higher risk of pseudoprogression (p = 0.0498). The overall salvage surgery rate was 17.7%. Conclusion: Upfront surgery may be more desirable than FSRT for those surgically fit patients with considerable treatment volume and evidence of mass effect. Large prospective studies are needed to confirm our findings and to identify further predictive factors for pseudoprogression.
引用
收藏
页码:152 / 159
页数:8
相关论文
共 50 条
  • [1] Radiosurgery and fractionated stereotactic radiotherapy of vestibular schwannoma
    Hamm, K.
    Herold, H-U.
    Surber, G.
    Rosahl, S.
    HNO, 2017, 65 (05) : 434 - 441
  • [2] Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma. Toxicity and Complications
    Perez Montero, H.
    Gascon, N.
    Guardado, S.
    Cabezas, A.
    D'Ambrosi, R.
    Rodriguez, V.
    Perez-Regadera, J.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S683 - S683
  • [3] Stereotactic fractionated radiotherapy and LINAC-Radiosurgery in the treatment of vestibular schwannoma
    Ladar, C
    Grosu, A
    Oestreicher, E
    Müller, A
    Arnold, A
    Molls, M
    RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S11 - S11
  • [4] Stereotactic fractionated radiotherapy and LINAC-radiosurgery in the treatment of vestibular schwannoma
    Ladar, C
    Grosu, A
    Fauser, C
    Oestreicher, E
    Pinsker, K
    Jaeger, R
    Staerk, S
    Arnold, W
    Lumenta, C
    Molls, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S313 - S314
  • [5] Stereotactic radiotherapy of vestibular schwannoma
    Putz, Florian
    Mueller, Jan
    Wimmer, Caterina
    Goerig, Nicole
    Knippen, Stefan
    Iro, Heinrich
    Grundtner, Philipp
    Eyuepoglu, Ilker
    Roessler, Karl
    Semrau, Sabine
    Fietkau, Rainer
    Lettmaier, Sebastian
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (03) : 200 - 212
  • [6] Stereotactic radiotherapy for vestibular schwannoma
    Muzevic, Dario
    Legcevic, Jelena
    Splavski, Bruno
    Caye-Thomasen, Per
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (12):
  • [7] Stereotactic Radiotherapy for Vestibular Schwannoma
    Sweeney, Patrick
    Yajnik, Santosh
    Hartsell, William
    Bovis, George
    Venkatesan, Jagannath
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2009, 42 (04) : 655 - +
  • [8] Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma
    Sakamoto, T
    Shirato, H
    Takeichi, N
    Aoyama, H
    Kagei, K
    Nishioka, T
    Fukuda, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (05): : 1295 - 1298
  • [9] LINAC-radiosurgery versus stereotactic fractionated radiotherapy in patients with vestibular Schwannoma
    Ladar, C
    Fauser, C
    Oestreicher, E
    Pinsker, K
    Jaeger, R
    Staerk, S
    Lumenta, C
    Arnold, W
    Molls, M
    Grosu, AL
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S260 - S260
  • [10] Role of surgical resection in combination with fractionated stereotactic radiotherapy for management of vestibular schwannoma
    Sawamura, Y
    Shirato, H
    Sakamoto, T
    NEURO-ONCOLOGY, 2005, 7 (03) : 392 - 392